Inhibition of human cholinesterases by drugs used to treat Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 17, Issue 2, 2003, Pages 117-126

  Darvesh, Sultan ^a,b,c,d   Walsh, Ryan ^a,b   Kumar, Rohit ^a   Caines, Angela ^b   Roberts, Sheila ^b   Magee, David ^c   Rockwood, Kenneth ^a   Martin, Earl ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MOUNT SAINT VINCENT UNIVERSITY   (Canada)

^c UNIVERSITY OF NEW BRUNSWICK   (Canada)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Acetylcholinesterase; Butyrylcholinesterase; Cholinesterase inhibitors

Indexed keywords

ACETYLCHOLINESTERASE; ACETYLTHIOCHOLINE; ARYL ACYLAMIDASE; BUTYRYLTHIOCHOLINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTERASE; GALANTAMINE; METRIFONATE; NEUROTRANSMITTER; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CHOLINESTERASE INHIBITION; COGNITIVE DEFECT; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; INHIBITION KINETICS; PRIORITY JOURNAL; SYMPTOMATOLOGY;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; ERYTHROCYTES; HUMANS; KINETICS; PLASMA;

EID: 0038308812     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200304000-00011     Document Type: Article

References (56)

1. Alhomida AS, Al-Rajhi AA, Kamal MA, et al. Kinetic analysis of the toxicological effect of tacrine (Cognex) on human retinal acetylcholinesterase activity. Toxicology 2000;147:33-9.
2. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002;47:64-70.
3. Bartus RT, Dean RLI, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-17.
4. Berman HA, Leonard K. Interaction of tetrahydroaminoacridine with acetylcholinesterase and butyrylcholinesterase. Mol Pharmacol 1992;41:412-8.
5. Burns A, Rossor M, Hecker J, et al. Donepezil in the treatment of Alzheimer's disease: results from a multinational clinical trial. Dement Geriatr Cogn Disord 1999;10:237-44.
6. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edition. Hillsdale, NJ: LEA, 1988.
7. Corey-Bloom J, Anand R, Veach J et al. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderate severe Alzheimer's disease. Int J Geriatr Psychiatry 1998;1:55-65.
8. Costagli C, Galli A. Inhibition of cholinesterase-associated aryl acylamidase activity by anticholinesterase agents: focus on drugs potentially effective in Alzheimer's disease. Biochem Pharmacol 1998; 55:1733-7.
9. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:1184-90.
10. Cummings JL, Cyrus PA, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease: Metrifonate Study Group. Neurology 1998;50:1214-21.
11. Darvesh S, Grantham DL, Hopkins DA. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J Comp Neurol 1998a;393:374-90.
12. Darvesh S, Kumar R, Roberts S, et al. Butyrylcholinesterase-mediated enhancement of the enzymatic activity of trypsin. Cell Mol Neurobiol 2001a;21:285-9.
13. Darvesh S, Kumar R, Caines A, et al. Enzyme kinetic properties of cholinesterase inhibitors used to treat Alzheimer's disease. Can J Neurol Sci 2001b;28(suppl):34.
14. Darvesh S, MacDonald SE, Losier AM, et al. Cholinesterases in cardiac ganglia and modulation of canine intrinsic cardiac neuronal activity. J Auton Nerv Syst 1998b;71:75-84.
15. Davis KL, Thai LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease: the Tacrine Collaborative Study Group. N Engl J Med 1992;327:1253-9.
16. Ellman GL, Courtney KD, Andres VJ, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-95.
17. Enz A, Amstutz R, Boddeke H, et al. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res 1993;98:431-8.
18. Fujimoto D. Serotonin-sensitive aryl acylamidase activity of acetylcholinesterase. FEBS Lett 1976;71:121-3.
19. George ST, Balasubramanian AS. The aryl acylamidases and their relationship to cholinesterases in human serum, erythrocyte and liver. Eur J Biochem 1982;121:177-86.
20. Giacobini E. From molecular structure to Alzheimer therapy. Jpn J Pharmacol 1997;74:225-41.
21. Giacobini E. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: Giacobini E, ed. Cholinesterases and Cholinesterase Inhibitors. London: Martin Dunitz, 2000:181-226.
22. Giacobini E. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging 2001;18: 891-8.
23. Greig NH, Utsuki T, Yu Q-S, et al. A new therapeutic target in Alzheimer's disease: attention to butyrylcholinesterase. Curr Med Res Opin 2001;17:159-65.
24. Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer's disease. Drugs 2001;61:41-52.
25. Guillozet AL, Smiley JF, Mash DC, et al. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997;42:909-18.
26. Hartz-Shütt CG, Mai JK. Cholinesterase-aktivität im menschlichen striatum unter besonderer berücksichtigung der insulae terminales. J Hirnforsch 1991;32:317-42.
27. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 2001;15:375-90.
28. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease: the Tacrine Study Group. JAMA 1994;271:985-91.
29. Krall WJ, Sramek JJ, Cutler NR. Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother 1999;33:441-50.
30. Mesulam MM, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994;36:722-7.
31. Mesulam M, Guillozet A, Shaw P, et al. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002;9:88-93.
32. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-30.
33. Nochi S, Asakawa N, Sato T. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020). Biol Pharm Bull 1995; 18:1145-7.
34. Op Den Velde W, Stam FC. Some cerebral proteins and enzyme systems in Alzheimer's presenile and senile dementia. J Am Geriatr Soc 1976;24:12-6.
35. Perry EK, Perry RH, Blessed G, et al. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978;4:273-7.
36. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54: 2261-8.
37. Reiner E, Radic Z. Mechanism of action of cholinesterase inhibitors. In: Giacobini E, ed. Cholinesterases and Cholinesterase Inhibitors. London: Martin Dunitz, 2000:103-19.
38. Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-95.
39. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998a;158:1021-31.
40. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease: Donepezil Study Group. Neurology 1998b;50:136-45.
41. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
42. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br Med J 1999;318:633-8.
43. Saxena A, Redman AM, Jiang X, et al. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry 1997;36:14642-51.
44. Segel IH. Biochemical Calculations. New York: John Wiley and Sons, 1976.
45. Shaw KTY, Utsuki T, Rogers J, et al. Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 2001;98:7605-10.
46. Silver A. The Biology of Cholinesterases. Amsterdam: Elsevier, 1974.
47. Sim A. Rivastigmine: a review. Hosp Med 1999;60:731-5.
48. Sugimoto H, Iimura Y, Yamanishi Y, et al. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J Med Chem 1995;38:4821-9.
49. Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991;253:872-9.
50. Svensson AL, Nordberg A. Tacrine and donepezil attenuate the neurotoxic effect of Aβ(25-35) in rat PC12 cells. NeuroReport 1998;9:1519-22.
51. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD: the Galantamine USA-10 Study Group. Neurology 2000;54:2269-76.
52. Thomsen T, Kaden B, Fischer JP, et al. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galantamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 1991;29:487-92.
53. Webb JL. Enzyme and Metabolic Inhibitors, vol. 1. New York: Academic Press, 1963:535-603.
54. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence of selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-6.
55. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. Br Med J 2000;321:1445-9.
56. Wright CI, Geula C, Mesulam M-M. Protease inhibitors and indolamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease. Proc Natl Acad Sci USA 1993;90:683-6.